Understanding how a protein linked to Parkinson's disease spreads in the brain
Activity-dependent release of human alpha-synuclein
This study is looking at how a protein linked to Parkinson's disease spreads in the brain, especially when the brain is under stress from things like injuries or lack of sleep, to find new ways to help slow down the disease for people living with it.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio University Athens NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10575119 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the release and spread of alpha-synuclein, a protein associated with Parkinson's disease. By examining how this protein behaves under different conditions, such as increased neuronal activity due to factors like traumatic brain injury or sleep deprivation, the study aims to uncover the genetic and molecular factors that influence its release. The researchers will use genetic models to better understand how mutations in alpha-synuclein affect its behavior and interactions in the nervous system. This knowledge could lead to new therapeutic targets for slowing or halting the progression of Parkinson's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with Parkinson's disease, particularly those with a history of traumatic brain injury or sleep deprivation.
Not a fit: Patients with neurodegenerative diseases unrelated to alpha-synuclein or those without any risk factors for Parkinson's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow or stop the progression of Parkinson's disease.
How similar studies have performed: Other research has shown promising results in understanding protein propagation in neurodegenerative diseases, making this approach both relevant and potentially impactful.
Where this research is happening
Athens, United States
- Ohio University Athens — Athens, United States (Active)
Researchers
- Principal investigator: Lee, Daewoo — Ohio University Athens
- Study coordinator: Lee, Daewoo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.